Regado nails down $20M for bleeding drug; Aerie kicks off PhII for glaucoma hopeful;

@FierceBiotech: Bioinformatics skills help Stanford beat Illumina to $40M stell cell genomics grant. Story from FierceBiotech IT | Follow @FierceBiotech

@JohnCFierce: Amgen clocks 5th straight win on PCSK9, well ahead of the competition. Credit where it's due--they went all out. Story | Follow @JohnCFierce

@DamianFierce: AbbVie's hep C program is in desperate need of a catchy nickname. "ABT-450/r + ABT-267 + ABT-333" less than rolls off the tongue. | Follow @DamianFierce

@EmilyMFierce: Exposure to acid turns regular adult cells into stem cells. Story from FierceBiotech Research | Follow @EmilyMFierce

> Regado Biosciences ($RGDO) landed $20 million in a private placement, money it'll use to fund an ongoing Phase III trial for its drug designed to control bleeding during coronary interventions. News

> The recently IPO'd Aerie Pharmaceuticals ($AERI) kicked off a Phase IIb study of PG324, a combination treatment for glaucoma. More

> The U.K.'s Summit is raising $20 million to bankroll the development of a muscular dystrophy therapeutic. Story

Medical Device News

@FierceMedDev: Accuray rebound continues with strong second-quarter results Story | Follow @FierceMedDev

@MarkHFierce: Medtronic's Infuse bone growth product continues to generate legal problems. Report via MassDevice | Follow @MarkHFierce

@GalenMoore: At VentureCafe today: quantumvr's handheld 3D scanner. Design, sure, but could it be used for diabetes? Photo | Follow @GalenMoore

@MichaelGFierce: | Follow @MichaelGFierce

@EmilyWFierce: FDA considering faster approval process for high-need medical devices. Report via MedPageToday | Follow @EmilyWFierce

> Abiomed's heart pump wins Chinese approval as revenue soars. Story

> Despite modest growth, Cepheid swings to a loss in Q4. Article

Pharma News

@FiercePharma: Daiichi Sankyo pledges 'drastic measures' to get Ranbaxy in line. Story | Follow @FiercePharma

@TracyStaton: BMS counts on DTC to keep driving Eliquis growth. But are its ads much different from rivals? News | Follow @TracyStaton

@EricPFierce: Lilly announced 1,000 job cuts in 2013. 2014 expected to be even bleaker. Report | Follow @EricPFierce

@CarlyHFierce: Sanofi wards off Lilly's Lantus challenger with infringement lawsuit. More | Follow @CarlyHFierce

> Abbott Labs cuts jobs at HQ and plans for plant closure in Puerto Rico. News

> Sanofi wards off Lilly's Lantus challenger with infringement lawsuit. Story

> Daiichi Sankyo pledges 'drastic measures' to get Ranbaxy in line. More

> Amgen cutting 200 jobs despite improved Epogen sales. Item

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.